Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica J Lin

Showing results (11-20 of 92) with videos related to

Pageof 10
Sort By:
Oncology and Therapy|December 18, 2024
A Podcast Discussion on the Intracranial Efficacy of Antibody-Drug Conjugates in Patients with EGFR-Mutated NSCLC with Brain MetastasesMelissa L Johnson, Jessica J Lin, Adrienne Boire, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 10, 2026
Brief Report: First-line Chemoimmunotherapy and Chemotherapy Outcomes in Patients with RET Fusion-Positive Lung Cancer in LIBRETTO-431Can Cui, Sabrina Lin, Sarah Waliany, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 3, 2016
Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIsJessica J Lin, Stephanie Cardarella, Christine A Lydon, et al.
AJR. American Journal of Roentgenology|December 31, 2019
Imaging Features and Metastatic Patterns of Advanced <i>ALK</i>-Rearranged Non-Small Cell Lung CancerDexter P Mendoza, Jessica J Lin, Marguerite M Rooney, et al.
Lung Cancer (Amsterdam, Netherlands)|February 11, 2026
Combination therapy with lorlatinib and mitogen-activated protein kinase pathway inhibition in previously treated ALK- or ROS1-rearranged lung cancerJaime L Schneider, Alona Muzikansky, Elizabeth Krueger, et al.
JTO Clinical and Research Reports|March 1, 2024
Efficacy and Safety of Dose-Escalated Alectinib in Patients With Metastatic ALK-Positive NSCLC and Central Nervous System Relapse on Standard-Dose AlectinibJustin M Cheung, Jiyoon Kang, Beow Y Yeap, et al.
International Journal of Radiation Oncology, Biology, Physics|November 22, 2024
Phase 2 Trial of Consolidative Stereotactic Body Radiation Therapy in Patients With Metastatic Oncogene-driven Non-small Cell Lung Carcinoma Treated With Tyrosine Kinase InhibitorsFlorence K Keane, Beow Y Yeap, Melin J Khandekar, et al.
JTO Clinical and Research Reports|April 7, 2023
Real-World Comparative Effectiveness of First-Line Alectinib Versus Crizotinib in Patients With Advanced <i>ALK</i>-Positive NSCLC With or Without Baseline Central Nervous System MetastasesQing Zhang, Jessica J Lin, Navdeep Pal, et al.
The Oncologist|July 17, 2025
ENIGMA+: a national, decentralized, remote consent study for clinical data and biospecimen collection in patients with ALK-positive advanced NSCLCJoyce Liang, Sarah Waliany, Andrew Do, et al.
Cancers|March 19, 2020
Imaging Features and Patterns of Metastasis in Non-Small Cell Lung Cancer with <i>RET</i> RearrangementsSubba R Digumarthy, Dexter P Mendoza, Jessica J Lin, et al.
Pageof 10

Showing results (11-20 of 92) with videos related to

Sort By:
Pageof 10
Oncology and Therapy|December 18, 2024
A Podcast Discussion on the Intracranial Efficacy of Antibody-Drug Conjugates in Patients with EGFR-Mutated NSCLC with Brain MetastasesMelissa L Johnson, Jessica J Lin, Adrienne Boire, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 10, 2026
Brief Report: First-line Chemoimmunotherapy and Chemotherapy Outcomes in Patients with RET Fusion-Positive Lung Cancer in LIBRETTO-431Can Cui, Sabrina Lin, Sarah Waliany, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 3, 2016
Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIsJessica J Lin, Stephanie Cardarella, Christine A Lydon, et al.
AJR. American Journal of Roentgenology|December 31, 2019
Imaging Features and Metastatic Patterns of Advanced <i>ALK</i>-Rearranged Non-Small Cell Lung CancerDexter P Mendoza, Jessica J Lin, Marguerite M Rooney, et al.
Lung Cancer (Amsterdam, Netherlands)|February 11, 2026
Combination therapy with lorlatinib and mitogen-activated protein kinase pathway inhibition in previously treated ALK- or ROS1-rearranged lung cancerJaime L Schneider, Alona Muzikansky, Elizabeth Krueger, et al.
JTO Clinical and Research Reports|March 1, 2024
Efficacy and Safety of Dose-Escalated Alectinib in Patients With Metastatic ALK-Positive NSCLC and Central Nervous System Relapse on Standard-Dose AlectinibJustin M Cheung, Jiyoon Kang, Beow Y Yeap, et al.
International Journal of Radiation Oncology, Biology, Physics|November 22, 2024
Phase 2 Trial of Consolidative Stereotactic Body Radiation Therapy in Patients With Metastatic Oncogene-driven Non-small Cell Lung Carcinoma Treated With Tyrosine Kinase InhibitorsFlorence K Keane, Beow Y Yeap, Melin J Khandekar, et al.
JTO Clinical and Research Reports|April 7, 2023
Real-World Comparative Effectiveness of First-Line Alectinib Versus Crizotinib in Patients With Advanced <i>ALK</i>-Positive NSCLC With or Without Baseline Central Nervous System MetastasesQing Zhang, Jessica J Lin, Navdeep Pal, et al.
The Oncologist|July 17, 2025
ENIGMA+: a national, decentralized, remote consent study for clinical data and biospecimen collection in patients with ALK-positive advanced NSCLCJoyce Liang, Sarah Waliany, Andrew Do, et al.
Cancers|March 19, 2020
Imaging Features and Patterns of Metastasis in Non-Small Cell Lung Cancer with <i>RET</i> RearrangementsSubba R Digumarthy, Dexter P Mendoza, Jessica J Lin, et al.
Pageof 10